Background: Chronic kidney disease (CKD) is associated with mineral metabolism dysregulation, cardiovascular disease, and premature mortality. No study specifically examined mineral metabolism trends in a generalizable sample of patients at increased CKD risk. 
C
hronic kidney disease (CKD) is associated with several complications, including mineral metabolism dysregulation, increased cardiovascular disease (CVD) morbidity, and premature mortality. Mineral metabolism abnormalities in dialysis patients present with persistently increased parathyroid hormone (PTH) levels, typically accompanied by hyperphosphatemia. More than half the patients with chronic kidney failure or end-stage renal disease treated with hemodialysis or peritoneal dialysis in several large observational studies showed hyperphosphatemia, a finding associated with increased mortality. association between phosphorus level greater than 3.5 mg/dL and mortality in patients with CKD. 7, 8 The direct or indirect mechanism by which greater serum phosphorus values and mortality are linked is not fully understood. Mineral metabolism dysregulation is a novel cardiovascular risk marker in patients with CKD because of associations with arterial stiffness, 9 vascular cal- cification, 9-11 myocardial infarction, 7 and cardiovascular mortality. 5 Even in individuals free of CKD and CVD in the community, greater serum phosphorus levels are associated with increased CVD risk.
12 However, no study specifically examined mineral metabolism trends in a generalizable sample of patients at increased risk of CKD. This study addresses these issues by using data from the National Kidney Foundation Kidney Early Evaluation Program (KEEP), a free voluntary community-based health screening program to raise kidney disease awareness and detect CKD for early disease intervention for high-risk individuals.
METHODS
This is a cross-sectional analysis of calcium, phosphorus, and PTH for the subset of KEEP participants with CKD stages 3, 4, and 5. KEEP enrolls people 18 years and older with a family history of kidney disease or a personal or family history of diabetes or hypertension. 13 Participants treated with dialysis or transplantation were excluded from these analyses. Parallel analyses using data from a sample population of the National Health and Nutrition Examination Survey (NHANES) 1999-2004 (n ϭ 1,438) were performed. KEEP and the NHANES database are fully described elsewhere in this supplement. 14 All participants provided informed consent before data collection. The Institutional Review Board at the Minneapolis Medical Research Foundation approved KEEP, including the research protocol, informed consent process, and data management procedures. A screening questionnaire was used to collect data for demographic characteristics, family and medical history, smoking habits, education level, access to physicians, and health insurance status. Detailed information for medication use was not obtained. The diagnostic panel included blood pressure, height and weight to calculate body mass index (BMI), and blood and urine collection. Estimated glomerular filtration rate (eGFR) was calculated 16 CVD was defined as self-reported heart attack, heart bypass surgery, heart angioplasty, stroke, heart failure, abnormal heart rhythm, or peripheral arterial disease (before May 2005). The slightly different definition of history of CVD in NHANES is self-reported history of coronary heart disease, angina/angina pectoris, heart attack, congestive heart failure, or stroke. World Health Organization (WHO) anemia is defined as hemoglobin level less than 13 g/dL (Ͻ130 g/L) for men and less than 12 g/dL (Ͻ120 g/L) for women. Normal PTH level (Kidney Disease Outcomes Quality Initiative [KDOQI] targets) 17 is 35 to 70 pg/mL for patients with CKD stage 3, 70 to 110 pg/mL for patients with stage 4, and 150 to 300 pg/mL for patients with stage 5 (values in ng/L are equivalent). Increased PTH level ). After excluding 376 participants for whom calcium, phosphorus, and PTH testing results were unavailable for the study period of November 1, 2005, to December 31, 2006, a total of 2,646 participants remained. Data are presented as mean Ϯ SD (SE for NHANES data) unless specified otherwise. Kruskal-Wallis test was used to test mean differences among eGFR groups. Multiple linear regressions were used to estimate the effect of each predictor on mean values for PTH, phosphorus, and calcium with and without control for eGFR. Predictors were age, sex, race, obesity, smoking status, education level, diabetes, hypertension, anemia, CVD, urinary albumin-creatinine ratio, normal phosphorus level, and normal calcium level. Logistic regression was used for odds ratios of increased PTH, increased phosphorus, and increased calcium levels. Predictors were the same as in multiple linear regressions, except for the interaction term between diabetes and obesity for PTH level only. Pearson correlation coefficients were calculated for eGFR with PTH, calcium, and phosphorus levels, respectively. Multiple linear regression of mean PTH as a continuous variable in KEEP by using 2 models (1 adjusted for eGFR) showed significantly greater PTH levels by the following characteris- tics: African American, older, obese, diabetes absent, WHO anemia, CVD, and albuminuria (Table 3) . Adjustment for level of kidney function decreased the coefficients for age, anemia, CVD, and albuminuria, but had little impact on obesity, African American race, and nondiabetic status. Increased PTH level was not significantly associated with sex, education level, tobacco use, or hypertension. Odds ratios for increased PTH levels were significantly increased for older participants, men, African Americans, obese participants, participants with lower eGFR, and participants with CVD ( Table 4 ). The association of obesity with greater PTH level was dependent on diabetes. For patients without diabetes, obesity was significantly associated with increased PTH level; for patients with diabetes, the association of obesity and increased PTH level was not significant. The relationship of obesity without diabetes and increased PTH level was independent of eGFR and race (data not shown).
RESULTS

Demographically
Multiple linear regression of mean phosphorus level (Table 5 ) as a continuous variable in KEEP by using 2 models (1 adjusted for eGFR) showed weaker associations than PTH level (Table 3) . Odds ratios for increased phosphorus levels were significantly greater for participants younger than 60 years, women, participants with high school education or less, and participants with lower eGFR (Table 6) . Similarly, multiple linear regression of mean calcium level (Table 7) showed weaker associations than those for PTH level. Odds ratios for increased calcium level were significantly increased for women, nonobese participants, diabetic participants, participants with hypertension, and participants without anemia (Table 8) .
DISCUSSION
These data confirm that as eGFR decreases, PTH level increases in a unique, large, community-based CKD screening program. Phosphorus level increase and calcium level decrease with kidney function loss is more gradual. The PTH level increase may be the result of end-organ resistance affecting normal feedback inhibition, minute increases in serum phosphorus levels within the normal range, or low vitamin D levels (not measured in this study).
18-20 These trends in calcium, phosphorus, and PTH by eGFR level are consistent with physiological expectations and previous studies. [18] [19] [20] Small phosphorus level increases from baseline ranging from 0.1 to 0.6 mg/dL (0.16 to 0.32 mmol/L) across kidney function levels independent of diet were found in more than 17,000 individuals using NHANES III (1988) (1989) (1990) (1991) (1992) (1993) (1994) data. 21 This study did not evaluate PTH and used a generally less accurate CockcroftGault creatinine clearance to assess kidney function. Cross-sectional data from a study of more than 1,800 patients, predominantly in primarycare clinics, showed that PTH level increases early in the course of CKD, accompanied by gradual alterations in calcium and phosphorus levels, with the important additional information that low 1,25-dihydroxyvitamin D 3 (calcitriol) 19 Its limitations include lack of serum creatinine calibration to the reference standard and an elderly population with a mean age older than 70 years. Data from 2 large outpatient nephrology clinics in Spain also showed similar trends in mineral metabolism parameters by eGFR.
20
The early increase in PTH level as eGFR decreases is significant enough to support PTH monitoring in patients with CKD. In this analysis of KEEP data, older age, African American race, obesity, nondiabetic status, anemia, CVD, and albuminuria with albumin-creatinine ratio of 30 mg/g or greater were associated with greater PTH levels, suggesting the need for more aggressive monitoring for these subgroups. Speculation is that low vitamin D levels contribute to these associations, as shown in other studies of patients with CKD. 19, 20, 22 In our study, adjustment for eGFR had little impact on the association of obesity, African American race, and nondiabetic status with increased PTH levels, whereas relationships of age, anemia, CVD, and albuminuria with greater PTH levels remained significant. These findings support the role of an independent variable, such as vitamin D levels, in those subgroups. Although the association of obesity with increased PTH level was independent of African American race and eGFR, it was dependent on the absence of diabetes. The relationship of obesity and PTH level in patients with CKD was also shown in a recent US Veteran's Administration study of adult men, which showed that higher BMI was associated with greater PTH level independently of age, race, diabetes status, serum calcium level, or serum phosphorus level.
23
Although the increase in phosphorus level is relatively small in both KEEP and NHANES, 2 other studies showed that similar increases of 0.5 to 1.0 mg/dL (0.16 to 0.32 mmol/L) were associated with increased mortality. 7, 8 In the prospective African American Study of Hypertension and Kidney Disease and a Veteran's Administration retrospective study, minute increases in phosphorus levels also were associated with CKD progression, both loss of kidney function deter- mineral metabolism evaluation in patients with CKD enrolled in Medicare before dialysis therapy. Conversely, abstraction of randomly selected charts for 300 hemodialysis and 180 peritoneal dialysis patients in a 2-month interval in 2006 showed calcium and phosphorus assessments in 90% or more of patients, 26 with no PTH evaluation in the report.
The strengths of this KEEP analysis include a large community-based population and reliable laboratory methods. Previously published studies of mineral metabolism in patients with CKD included patients from dialysis units, nephrology CKD practices, or primary care clinics. This description of trends in mineral metabolism for a community-based population at increased risk of CKD is unique. Serum creatinine was calibrated to the MDRD Study central laboratory to increase the accuracy of eGFR, as described elsewhere in this supplement. 15 Calcium and phosphorus laboratory methods generally are reliable. Although this analysis does not include serum calcium corrected for albumin level, total serum calcium level may be as accurate an assessment of calcium status as corrected calcium formulas. 27 PTH assays have important interassay variability owing to antibody specificity and standardization reasons. 28 The PTH assays in KEEP Immulite 2000 and NHANES Elecsys 1010 behave similarly in published interassay comparison data, including a total of 14 assays. 28 The similar trends in mineral metabolism dysregulation with decreasing eGFR between KEEP and NHANES support the overall generalizability of the KEEP cohort. Greater PTH levels may reflect more African Americans with characteristically greater PTH levels in the KEEP cohort. 22, 23 Study limitations include the absence of outcomes data because incidences of death and end-stage renal disease are too low to be assessed meaningfully within the study period. The KEEP database was started August 1, 2000, but data for mineral metabolism parameters are available only beginning November 1, 2005. The association of small, but significant, increases in phosphorus levels with mortality and CKD progression in other studies raises the potential contribution of progression bias and competing death bias with these cross-sectional results, which cannot be assessed using the currently available data.
A single assessment in this study has limitations for the reproducibility of eGFR to detect §Parathyroid hormone, 35 to 70 pg/mL for patients with stage 3, 70 to 110 pg/mL for patients with stage 4, and 150 to 300 pg/mL for patients with stage 5 (values in ng/L are equivalent).
ʈPhosphorus, 2.7 to 4.6 mg/dL (0.87 to 1.49 mmol/L) for patients with stages 3 and 4 and 3.5 to 5.5 mg/dL (1.13 to 1.78 mmol/L) for patients with stage 5.
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CKD, particularly at or near the diagnostic threshold of 60 mL/min/1.73 m 2 (1.0 mL/s/1.73 m 2 ), because 2 evaluations 3 or more months apart are required to define the condition. Individuals with eGFR at this level or greater were excluded from the analysis so that isolated albuminuria was not used to define CKD. KEEP has limited medication data, but the prevalence of drug therapy relevant to mineral metabolism in a population with 6.7% awareness of CKD is likely to be low. Last, KEEP includes no assessment of diet or vitamin D levels.
In a community-based CKD screening population, increased PTH levels occur early in patients with CKD stage 3, typically in the presence of normal calcium and phosphorus levels. Early abnormalities in mineral metabolism support early dietary phosphorus restriction to maintain homeostasis 29 and the need for PTH monitoring even in the presence of normal calcium and phosphorus levels.
